Holen Sie sich die Stockscreener-App
1.07
0.94%
0.01
Schlusskurs vom Vortag:
$1.06
Offen:
$1.06
24-Stunden-Volumen:
1.13M
Relative Volume:
0.81
Marktkapitalisierung:
$270.61M
Einnahmen:
$14.78M
Nettoeinkommen (Verlust:
$-64.01M
KGV:
-3.7243
EPS:
-0.2873
Netto-Cashflow:
$-22.59M
1W Leistung:
-2.73%
1M Leistung:
-12.30%
6M Leistung:
-35.54%
1J Leistung:
+4.90%
1-Tages-Spanne:
$1.05
$1.09
1-Wochen-Bereich:
$1.05
$1.15
52-Wochen-Spanne:
$1.00
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
Firmenname
Lineage Cell Therapeutics Inc
Sektor
Branche
Telefon
510-871-4188
Adresse
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.07 | 278.20M | 14.78M | -64.01M | -22.59M | -0.2873 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-20 | Eingeleitet | Craig Hallum | Buy |
| 2022-11-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-14 | Eingeleitet | B. Riley Securities | Buy |
| 2021-08-19 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-03-31 | Eingeleitet | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten
Lineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript - The Globe and Mail
Lineage Cell Therapeutics Q3 EPS Reduced by HC Wainwright - MarketBeat
Lineage Cell Therapeutics Q2 Earnings Call Highlights - MarketBeat
CCORF Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Lineage Cell Therapeutics, Inc. (LCTX) stock price, news, quote and history - Yahoo Finance Australia
Lineage Cell Therapeutics Balances Progress and Risk - TipRanks
Lineage Cell Therapeutics (LCTX) Stock Faces Cash Burn Despite Paper Profit - Sahm
Lineage Cell Therapeutics Inc (LCTX) Stock News Today - tradingkey.com
Lineage Cell Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
Lineage Cell Therapeutics Inc (LCTX) (Q2 2026) Earnings Call Hig - GuruFocus
LCTX Looks 13.7% Undervalued on GF Value™ - GuruFocus
Transcript : Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 - marketscreener.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Earnings call transcript: Lineage Cell Therapeutics posts Q2 2026 profit, extends runway - Investing.com
Lineage Cell (LCTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Lineage Cell: Q2 Earnings Snapshot - marketscreener.com
[10-Q] Lineage Cell Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Lineage Cell Therapeutics (LCTX) Holds Above $1.07 Support as Biotech ConsolidatesFloat Adjusted Cap - dars.gov.et
3 Penny Stocks With Market Caps Larger Than $40M To Watch - webull.com
Lineage Cell Therapeutics, Inc. Revenue Breakdown – AMEX:LCTX - TradingView
Earnings Preview: LCTX to Report Financial Results Post-market on August 06 - Moomoo
Lineage Cell Therapeutics to announce Q2 2026 results on August 6 with business update call - Traders Union
Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - Yahoo Finance
BlackRock, Inc. (LCTX) discloses 5.3% beneficial ownership in Lineage Cell - Stock Titan
Lineage Cell Therapeutics Inc (LCTX) Income Statement - tradingkey.com
Lineage Cell Therapeutics Inc (LCTX) Cash Flow - TradingKey
Lineage Cell Therapeutics Inc - TradingKey
LCTX|Lineage Cell Therapeutics Inc|Price:1.035|Chg%:+0.005 - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Balance Sheet - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lineage Cell Therapeutics (LCTX) Slips 3.74% as Stock Tests Key Support LevelsOBV Trend Line - dars.gov.et
Lineage Cell Therapeutics, Inc. Revenue Breakdown – SWB:BT3 - TradingView
Lineage Cell Therapeutics, Inc. Revenue Breakdown – LS:A2PP89 - TradingView
LCTX|Lineage Cell Therapeutics Inc|Price:1.030|Chg%:-0.035 - TradingKey
Lineage Cell Therapeutics Inc (LCTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OpRegen regenerative medicine program showcased at major vision event by Lineage Cell Therapeutics - Traders Union
Lineage Cell Therapeutics (LCTX) Edges Lower as Stock Hovers Near Key SupportFibonacci Retracement - dars.gov.et
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating - Moomoo
Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject’ Cell Therapy Plan - Yahoo Finance
Lineage Cell advances corneal cell therapy program to animal testing - Investing.com
Lineage Cell advances corneal cell therapy program to animal testing By Investing.com - Investing.com Nigeria
Lineage Cell Therapeutics advances COR1 preclinical program for corneal endothelial disease - Traders Union
Lineage Cell Therapeutics Provides Update On COR1 Cell Therapy Program For Corneal Endothelial Disease - marketscreener.com
Lineage Cell Updates on COR1 for Corneal Endothelial Disease Tre - GuruFocus
Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease - Business Wire
New COR1 cell therapy aims to ease global shortage of corneal transplants - Stock Titan
Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit - BioSpace
Finanzdaten der Lineage Cell Therapeutics Inc-Aktie (LCTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):